The FDA has accepted AstraZeneca (NASDAQ:AZN) and Daiichi Sankyo’s biologics license application for priority review of its drug datopotamab deruxtecan, also known as Dato-DXd, for the treatment of EGFR-mutated lung cancer.
Companies seek to have Dato-DXd approval




